Back to Search
Start Over
Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
- Source :
-
International journal of geriatric psychiatry [Int J Geriatr Psychiatry] 2015 May; Vol. 30 (5), pp. 505-13. Date of Electronic Publication: 2014 Jul 07. - Publication Year :
- 2015
-
Abstract
- Objective: We compared amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) in subjects clinically diagnosed with Alzheimer's disease (AD), mild cognitive impairment (MCI), and older healthy controls (OHC) in order to test how these imaging biomarkers represent cognitive decline in AD.<br />Methods: Fifteen OHC, 19 patients with MCI, and 19 patients with AD were examined by [(18)F]florbetapir PET to quantify the standard uptake value ratio (SUVR) as the degree of amyloid accumulation, by MRI and the voxel-based specific regional analysis system for AD to calculate z-score as the degree of entorhinal cortex atrophy, and by mini-mental state examination (MMSE) and Alzheimer's Disease Assessment Scale-cognitive component--Japanese version (ADAS-Jcog) for cognitive functions.<br />Results: Both cutoff values for measuring AD-like levels of amyloid (1.099 for SUVR) and entorhinal cortex atrophy (1.60 for z-score) were well differentially diagnosed and clinically defined AD from OHC (84.2% for SUVR and 86.7% for z-score). Subgroup analysis based on beta-amyloid positivity revealed that z-score significantly correlated with MMSE (r = -0.626, p < 0.01) and ADAS-Jcog (r = 0.691, p < 0.01) only among subjects with beta-amyloid.<br />Conclusions: This is the first study to compare [(18)F]florbetapir PET and MRI voxel-based analysis of entorhinal cortex atrophy for AD. Both [(18)F]florbetapir PET and MRI detected changes in AD compared with OHC. Considering that entorhinal cortex atrophy correlated well with cognitive decline only among subjects with beta-amyloid, [18F]florbetapir PET makes it possible to detect AD pathology in the early stage, whereas MRI morphometry for subjects with beta-amyloid provides a good biomarker to assess the severity of AD in the later stage.<br /> (Copyright © 2014 John Wiley & Sons, Ltd.)
- Subjects :
- Aged
Aged, 80 and over
Aniline Compounds metabolism
Biomarkers metabolism
Brief Psychiatric Rating Scale
Case-Control Studies
Cognitive Dysfunction diagnostic imaging
Cognitive Dysfunction pathology
Diagnosis, Differential
Ethylene Glycols metabolism
Female
Humans
Male
Middle Aged
Alzheimer Disease diagnostic imaging
Alzheimer Disease pathology
Alzheimer Disease psychology
Amyloid beta-Peptides metabolism
Atrophy pathology
Entorhinal Cortex pathology
Magnetic Resonance Imaging methods
Positron-Emission Tomography methods
Subjects
Details
- Language :
- English
- ISSN :
- 1099-1166
- Volume :
- 30
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- International journal of geriatric psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- 25043833
- Full Text :
- https://doi.org/10.1002/gps.4173